Elevance Health (NYSE: ELV) revenue
Elevance Health reported revenue of $199,125m for fiscal 2025, 12.5% more than in fiscal 2024 ($177,011m). Since fiscal 2016 its revenue has grown by 134.6%, an average growth of 9.9% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $199,125m | +12.5% | $7,199m | 3.6% |
| 2024 | $177,011m | +3.3% | $7,862m | 4.4% |
| 2023 | $171,340m | +9.4% | $8,499m | 5.0% |
| 2022 | $156,595m | +13.0% | $8,283m | 5.3% |
| 2021 | $138,639m | — | $7,559m | 5.5% |
| 2019 | $104,213m | +13.1% | $5,999m | 5.8% |
| 2018 | $92,105m | +2.3% | $5,426m | 5.9% |
| 2017 | $90,040m | +6.1% | $4,175m | 4.6% |
| 2016 | $84,863m | — | $4,801m | 5.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Elevance Health
- How much revenue did Elevance Health make in fiscal 2025?
- Elevance Health reported revenue of $199,125m for fiscal 2025, compared with $177,011m in fiscal 2024.
- How much has the revenue of Elevance Health grown?
- Between fiscal 2016 and fiscal 2025 it went from $84,863m to $199,125m: 134.6% more, an average growth of 9.9% a year.
- What was the best year for revenue at Elevance Health?
- Of its last 9 fiscal years, fiscal 2025, with $199,125m.
- Where do the figures for Elevance Health come from?
- From the annual report (Form 10-K) that Elevance Health files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Elevance Health files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2019 · 2018 · 2017 · 2016. More on Elevance Health: the Elevance Health page · annual accounts · net income · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.